HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by NAND, S. L. Articles by HELLER, G. Z. Search for Related Content PubMed PubMed Citation Articles by NAND, S. L. Articles by HELLER, G. Z.

Bone Density Effects of Continuous Estrone Sulfate and Varying Doses of Medroxyprogesterone Acetate

From the School of Obstetrics & Gynaecology, and Sydney Menopause Centre, Royal Hospital for Women, Randwick, Australia, and the Department of Statistics, Macquarie University, Sydney, Australia.

Address reprint requests to: Swaran Nand, FRACOG School of Obstetrics and Gynecology Royal Hospital for Women Barker Street Randwick NSW 2031 Australia E-mail: menopthw{at}magna.com.au

Objective: To establish the optimum oral daily dose of medroxyprogesterone acetate with estrone sulfate for 2 years to maintain bone density.

Methods: A multicenter, double-blind study involved 568 postmenopausal women given estrone sulfate, 1.25 mg, and randomized to receive 2.5, 5, or 10 mg of medroxyprogesterone acetate. Bone density analyses of the lumbar spine and femoral neck were done at baseline and 12 and 24 months.

Results: There was a significant increase from baseline to 24 months in mean lumbar spine (4.0% ± 0.27%) and femoral neck (3.2% ± 0.28%) bone density, with no significant differences between the treatment groups. Factors most influencing bone density changes were baseline bone density and treatment duration. Significant increases were seen in the spine over 2 years; in the hip, those occurred in the first 12 months only. In both sites, lower baseline bone density resulted in greater increases. In the spine only, no previous hormone replacement therapy, higher body mass index, more than 2 years postmenopause, and nonsmoking resulted in greater gains. Once those covariates and center-to-center variations were corrected for, in the spine, the 10-mg group had smaller increases than the other groups. Changes were unrelated to age, parity, calcium, and alcohol intakes in either site.

Conclusion: Daily estrone sulfate, 1.25 mg, with 2.5, 5, or 10 mg medroxyprogesterone acetate was effective for preventing bone loss in postmenopausal women.

This article has been cited by other articles:

				S. M. Ott, D. Scholes, A. Z. LaCroix, L. E. Ichikawa, C. K. Yoshida, and W. E. Barlow Effects of Contraceptive Use on Bone Biochemical Markers in Young Women J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 179 - 185. [Abstract] [Full Text]